Your browser doesn't support javascript.
Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
Rev Esp Quimioter ; 34(4): 337-341, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1317435
Semantic information from SemMedBD (by NLM)
1. tocilizumab TREATS COVID-19
Subject
tocilizumab
Predicate
TREATS
Object
COVID-19
2. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
3. tocilizumab TREATS Patients
Subject
tocilizumab
Predicate
TREATS
Object
Patients
4. siltuximab INHIBITS interleukin-6
Subject
siltuximab
Predicate
INHIBITS
Object
interleukin-6
5. siltuximab TREATS 2019 novel coronavirus
Subject
siltuximab
Predicate
TREATS
Object
2019 novel coronavirus
6. 2019 novel coronavirus PROCESS_OF Patients
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Patients
7. siltuximab ADMINISTERED_TO Patients
Subject
siltuximab
Predicate
ADMINISTERED_TO
Object
Patients
8. tocilizumab TREATS Pneumonia caused by SARS-CoV-2
Subject
tocilizumab
Predicate
TREATS
Object
Pneumonia caused by SARS-CoV-2
9. Pneumonia caused by SARS-CoV-2 PROCESS_OF Patients
Subject
Pneumonia caused by SARS-CoV-2
Predicate
PROCESS_OF
Object
Patients
10. tocilizumab TREATS COVID-19
Subject
tocilizumab
Predicate
TREATS
Object
COVID-19
11. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
12. tocilizumab TREATS Patients
Subject
tocilizumab
Predicate
TREATS
Object
Patients
13. siltuximab INHIBITS interleukin-6
Subject
siltuximab
Predicate
INHIBITS
Object
interleukin-6
14. siltuximab TREATS 2019 novel coronavirus
Subject
siltuximab
Predicate
TREATS
Object
2019 novel coronavirus
15. 2019 novel coronavirus PROCESS_OF Patients
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Patients
16. siltuximab ADMINISTERED_TO Patients
Subject
siltuximab
Predicate
ADMINISTERED_TO
Object
Patients
17. tocilizumab TREATS Pneumonia caused by SARS-CoV-2
Subject
tocilizumab
Predicate
TREATS
Object
Pneumonia caused by SARS-CoV-2
18. Pneumonia caused by SARS-CoV-2 PROCESS_OF Patients
Subject
Pneumonia caused by SARS-CoV-2
Predicate
PROCESS_OF
Object
Patients
ABSTRACT

OBJECTIVE:

The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare.

METHODS:

Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab.

RESULTS:

The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%).

CONCLUSIONS:

Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Monoclonal Type of study: Etiology study / Clinical Practice Guide / Observational study / Risk factors Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Rev Esp Quimioter Journal subject: Drug Therapy Year: 2021 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Monoclonal Type of study: Etiology study / Clinical Practice Guide / Observational study / Risk factors Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Rev Esp Quimioter Journal subject: Drug Therapy Year: 2021 Document Type: Article